Table 2.
Component | N* | Estimated least squares mean change scores of the PHQ-9† | Estimated differences of change scores (95% CI) |
Effect size for Baseline-Week eight change scores‡ (95% CI) |
Effect size for differences of change scores and their p values‡ (95% CI) |
P value | |||||||
Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | ||||||
SM | |||||||||||||
Presence | 544 | −0.79 | −1.31 | −1.50 | −1.86 | −1.70 | −1.75 | −1.79 | −1.88 | 0.19 (−0.29 to 0.67) | −0.65 (−0.78 to -0.53) | 0.05 (−0.07 to 0.16) | 0.44 |
Absence | 549 | −1.08 | −1.34 | −1.41 | −1.48 | −1.51 | −1.67 | −1.86 | −2.07 | −0.78 (−0.92 to -0.65) | |||
BA | |||||||||||||
Presence | 552 | −0.85 | −1.33 | −1.42 | −1.64 | −1.60 | −1.79 | −1.85 | −2.06 | −0.17 (−0.65 to 0.31) | −0.73 (−0.86 to -0.60) | −0.04 (−0.16 to 0.08) | 0.50 |
Absence | 541 | −1.01 | −1.31 | −1.49 | −1.70 | −1.61 | −1.63 | −1.79 | −1.90 | −0.70 (−0.84 to -0.57) | |||
CR | |||||||||||||
Presence | 544 | −0.94 | −1.05 | −1.40 | −1.60 | −1.40 | −1.47 | −1.83 | −2.02 | −0.08 (−0.56 to 0.40) | −0.75 (−0.89 to -0.62) | −0.02 (−0.14 to 0.10) | 0.74 |
Absence | 549 | −0.93 | −1.60 | −1.52 | −1.74 | −1.82 | −1.95 | −1.82 | −1.94 | −0.68 (−0.81 to -0.56) | |||
AT | |||||||||||||
Presence | 547 | −0.75 | −1.31 | −1.30 | −1.56 | −1.71 | −1.61 | −1.73 | −1.85 | 0.25 (−0.23 to 0.73) | −0.67 (−0.80 to -0.54) | 0.06 (−0.06 to 0.18) | 0.31 |
Absence | 546 | −1.12 | −1.34 | −1.62 | −1.78 | −1.50 | −1.81 | −1.91 | −2.10 | −0.76 (−0.89 to -0.63) | |||
PS | |||||||||||||
Presence | 546 | −0.80 | −1.38 | −1.48 | −1.63 | −1.63 | −1.74 | −1.86 | −1.91 | 0.14 (−0.34 to 0.62) | −0.71 (−0.84 to -0.57) | 0.03 (−0.08 to 0.15) | 0.56 |
Absence | 547 | −1.07 | −1.27 | −1.44 | −1.71 | −1.58 | −1.69 | −1.79 | −2.05 | −0.72 (−0.86 to −0.60) |
*In a factorial trial design, all 1093 participants included in the analysis were randomly assigned 1:1 to either presence or absence of each component.
†Minus value indicates depression reduction.
‡We calculated effect sizes (standardised mean differences) using the baseline SD for within-group change score and the week 8 SD for group differences.
AT, assertion training; BA, behavioural activation; CIDI, Composite International Diagnostic Interview; CR, cognitive restructuring; PHQ-9, Patient Health Questionnaire-9; PS, problem-solving; SM, self-monitoring